메뉴 건너뛰기




Volumn 46, Issue 8, 1998, Pages 729-731

Clinical relevance of reduced bioavailability of rifampicin

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

EID: 0032129604     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (2)

References (25)
  • 1
    • 0025612647 scopus 로고
    • Tubercuosis in India, past. present and future
    • Fox W. Tubercuosis in India, past. present and future, Ind J Tub 1990; 37 : 175-213.
    • (1990) Ind J Tub , vol.37 , pp. 175-213
    • Fox, W.1
  • 2
    • 0024364436 scopus 로고
    • Rifmpicin raw material characteristics and their effect on bioavailability
    • Cavenaghi R. Rifmpicin raw material characteristics and their effect on bioavailability. Bull Int Un A TB Lung Dis 1989; 64 : 36-7.
    • (1989) Bull Int Un A TB Lung Dis , vol.64 , pp. 36-37
    • Cavenaghi, R.1
  • 4
    • 0024394983 scopus 로고
    • Human bioavailability studies
    • Acocella G. Human bioavailability studies. Bull Int Un A TB Lung Dis 1989; 64: 38-40.
    • (1989) Bull Int Un A TB Lung Dis , vol.64 , pp. 38-40
    • Acocella, G.1
  • 5
    • 0017944237 scopus 로고
    • Clinical Pharmacokinetics of rifampicin
    • Acocella G. Clinical Pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3 : 108-27.
    • (1978) Clin Pharmacokinet , vol.3 , pp. 108-127
    • Acocella, G.1
  • 6
    • 0021029934 scopus 로고
    • Effect of food on bioavailability of rifampicin
    • Polasa K, Krishnaswamy K. Effect of food on bioavailability of rifampicin. J Clin Pharmacol 1983; 23 : 433-7.
    • (1983) J Clin Pharmacol , vol.23 , pp. 433-437
    • Polasa, K.1    Krishnaswamy, K.2
  • 7
    • 0028919860 scopus 로고
    • Study of effect of concomitant food on bioavailability of rifampicin. isoniazid and pyrazinamide
    • Zent C, Smith P. Study of effect of concomitant food on bioavailability of rifampicin. isoniazid and pyrazinamide. Tubercle Lung Dis 1995; 76 : 109-17.
    • (1995) Tubercle Lung Dis , vol.76 , pp. 109-117
    • Zent, C.1    Smith, P.2
  • 8
    • 0024618644 scopus 로고
    • A study of blood rifampicin concentrations in smoking and non-smoking healthy individuals and in patients with tuberculosis
    • Xie ZY. A study of blood rifampicin concentrations in smoking and non-smoking healthy individuals and in patients with tuberculosis. Chung Hua Chieh Ho Ho Hsi Tsa Chih 1989; 12 : 3-5.
    • (1989) Chung Hua Chieh Ho Ho Hsi Tsa Chih , vol.12 , pp. 3-5
    • Xie, Z.Y.1
  • 10
    • 0029840906 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of the antimycobacterial drugs
    • Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clinics in Lab Med 1996; 16 : 717-29.
    • (1996) Clinics in Lab Med , vol.16 , pp. 717-729
    • Peloquin, C.A.1
  • 11
    • 24544448750 scopus 로고    scopus 로고
    • Pharmacokinetics of antituberculotics in TB patients with AIDS and diarrhea
    • Choudhri S, Hawken M, Gathu S, et al. Pharmacokinetics of antituberculotics in TB patients with AIDS and diarrhea. Amer J Resp Crit Care Med 1996; 153 : A491.
    • (1996) Amer J Resp Crit Care Med , vol.153
    • Choudhri, S.1    Hawken, M.2    Gathu, S.3
  • 13
    • 0026531077 scopus 로고
    • Pharmacokinetic drug interactions with rifampicin
    • Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clinical Pharmacokinet 1992; 22 : 47-65.
    • (1992) Clinical Pharmacokinet , vol.22 , pp. 47-65
    • Venkatesan, K.1
  • 14
    • 0016680298 scopus 로고
    • Mechanism of inhibitory effect of PAS granules on the absorption of rifampicin : Adsorption of rifampicin by an excipient, bentonite
    • Bowman G, Lundgren, Stjerstorm G. Mechanism of inhibitory effect of PAS granules on the absorption of rifampicin : Adsorption of rifampicin by an excipient, bentonite. Europ J Clin Pharmacol 1975; 8 : 293-9.
    • (1975) Europ J Clin Pharmacol , vol.8 , pp. 293-299
    • Bowman, G.1    Lundgren2    Stjerstorm, G.3
  • 15
    • 0027530359 scopus 로고
    • Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis
    • Jain A, Mehta VL, Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tuber Lung Dis 1993; 74 : 87-90.
    • (1993) Tuber Lung Dis , vol.74 , pp. 87-90
    • Jain, A.1    Mehta, V.L.2    Kulshrestha, S.3
  • 16
  • 17
    • 0028031172 scopus 로고
    • Cliniclly significant drug interactions with antituberculosis agents
    • Grange JM, Winstanley PA, Davies PDO. Cliniclly significant drug interactions with antituberculosis agents. Drug Safety 1994; 11 : 242-51.
    • (1994) Drug Safety , vol.11 , pp. 242-251
    • Grange, J.M.1    Winstanley, P.A.2    Davies, P.D.O.3
  • 23
    • 0025202620 scopus 로고
    • Drug combinations and the bioavailability of rifampicin
    • Fox W. Drug combinations and the bioavailability of rifampicin. Tubercle 1990; 71 : 243-5.
    • (1990) Tubercle , vol.71 , pp. 243-245
    • Fox, W.1
  • 24
    • 0029840906 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of the antimycobacterial drugs
    • Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clinics in Lab Med 1996; 16 : 717-29.
    • (1996) Clinics in Lab Med , vol.16 , pp. 717-729
    • Peloquin, C.A.1
  • 25
    • 0029003888 scopus 로고
    • Fixed-dose combinations of antituberculous medications to prevent drug resistance
    • Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122 : 951-4.
    • (1995) Ann Intern Med , vol.122 , pp. 951-954
    • Moulding, T.1    Dutt, A.K.2    Reichman, L.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.